DELFI Diagnostics Company Research Report

Company Overview

Name: DELFI Diagnostics

Mission of the Company:
DELFI Diagnostics is committed to advancing early cancer detection and reducing cancer mortality by leveraging fragmentomics technology combined with advanced machine learning. Their mission focuses on making cancer detection widely accessible and enhancing screening methods to improve patient outcomes.

Founded: No information is available.

Founders and Key People:

• Victor Velculescu, MD, PhD - Founder and Board Director

• Susan Tousi - Chief Executive Officer

• Nicholas C. Dracopoli, PhD - Chief Scientific Officer and Co-founder

• Peter B. Bach, MD - Chief Medical Officer

• Tobias Mann, PhD - Vice President, Software Engineering

• Allison Ryan, PhD - Vice President, Data Science

• Rob Scharpf, PhD - Head of Data Science and Co-founder

Headquarters:

• 1810 Embarcadero Road, Suite 100, Palo Alto, CA 94303

• 2809 Boston Street, Suite 503, Baltimore, MD 21224

Number of Employees: No information is available.

Revenue of the Company: No information is available.

What is the Company Known For:
DELFI Diagnostics is known for pioneering a novel approach to cancer detection involving liquid biopsy, a method analyzing fragments of cell-free DNA to detect cancer early, leveraging advanced machine learning and fragmentomics.

Products

What Products Do They Offer:
DELFI offers advanced liquid biopsy tests, with their leading product being the FirstLook Lung test.

High Level Description of the Product:
The FirstLook Lung test is a laboratory-developed blood test designed to enhance lung cancer screening. It analyzes DNA fragment patterns in the blood, using a whole-genome sequencing and machine learning approach.

Key Features of Each of the Products:

• FirstLook Lung Test:

• High sensitivity and negative predictive value of 99.8%

• It integrates provisionally with routine health checks

• Involves whole-genome sequencing

• Supports enhanced lung cancer detection through liquid biopsy

Recent Developments

What are the Recent Developments in the Company:

• Innovative fragmentomics approach with promising results for early cancer detection showcased in multiple publications.

• Recent partnerships and collaborations aimed at enhancing cancer screening rates and developing new products.

What are the New Products Launched:

• FirstLook Lung Test: Launched in October 2023, provides a new approach to lung cancer screening accessible via a blood test.

What are the New Features Added to the Existing Products:
The FirstLook Lung test employs advanced fragmentomics and machine learning techniques, allowing broader scanning for cancer-related DNA fragments opposed to traditional methods targeting known mutations.

Any New Partnerships etc:

• Collaboration with entities such as Indigenous Pact and City of Hope to improve cancer screening efforts in various communities.

• Partnership with Lahey Hospital & Medical Center for the administration of the new lung cancer screening test.

• Collaborative efforts with OSF HealthCare, Florida Lung Health Coalition, and others to improve screening accessibility and methodology.

This detailed report encapsulates all available current and relevant data regarding DELFI Diagnostics and reflects their strategic focus on enhancing cancer screening through innovative technologies.